PDCD1 and lung carcinoma: In patients with lung cancer with a partial response to anti-PD-1 the authors observed higher GP73 T-cell levels associated with better anti-PD-1 efficacy indicating potential to use GP73 expression in T-cells as a biomarker to assess patient response to immunotherapy.